Animal health pharmaceutical industry

被引:2
作者
Carnevale, RA
Shryock, TR
机构
[1] Inst Anim Hlth, Washington, DC 20005 USA
[2] Elanco Anim Hlth, Greenfield, IN 46140 USA
关键词
antimicrobial; usage; animal; health;
D O I
10.1016/j.prevetmed.2005.09.009
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The animal health pharmaceutical industry has proactively reported on the volumes of member company antimicrobial active ingredients sold in the U.S. At the individual company level, reporting of finished product distribution data to the FDA is a regulatory requirement, with applications to surveillance and pharmacovigilance. An accounting of product manufactured is done for purposes of good business practices, as well as marketing analyses. Additional applications of antimicrobial usage data might include use in risk assessments, such as for the FDA's Center for Veterinary Medicine Guidance for Industry #152 for the evaluation of the microbiological safety of antimicrobials intended for use in food animals. Compilation of national usage data will be a complex undertaking, hindered by issues such as confidentiality, auditing, field use practice variations, population dynamics (e.g. disease incidence, market conditions for poultry and livestock production), and generic usage. The amounts or volumes in pounds should be considered relative to the large number of animals under husbandry in the United States. Large volumes might seem impressive unless put into proper context. Until such time as a clearly defined application of national usage data is agreed, it is recommended that local usage programs will provide more useful information to perpetuate prudent antimicrobial use in animals. (C) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:217 / 220
页数:4
相关论文
共 50 条
  • [31] Comparative assessment of the human and animal health surveillance systems in Tanzania: Opportunities for an integrated one health surveillance platform
    Mremi, Irene R.
    Rumisha, Susan F.
    Sindato, Calvin
    Kimera, Sharadhuli, I
    Mboera, Leonard E. G.
    [J]. GLOBAL PUBLIC HEALTH, 2023, 18 (01)
  • [32] Nepeta-derived essential oils: From pharmaceutical to pesticide industry
    Mondal, Sankhadeep
    Roy, Somnath
    Babu, Azariah
    Pandey, Abhay K.
    [J]. SOUTH AFRICAN JOURNAL OF BOTANY, 2025, 179 : 318 - 333
  • [33] Market failure in the pharmaceutical industry and how it can be overcome: the CureShare mechanism
    Levy, Moshe
    Rizansky, Adi
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (02) : 143 - 156
  • [34] Peering into the pharmaceutical "pipeline": Investigational drugs, clinical trials, and industry priorities
    Fisher, Jill A.
    Cottingham, Marci D.
    Kalbaugh, Corey A.
    [J]. SOCIAL SCIENCE & MEDICINE, 2015, 131 : 322 - 330
  • [35] Regulating Pharmaceutical Industry Marketing: Development, Enforcement, and Outcome of Marketing Rules
    Mulinari, Shai
    [J]. SOCIOLOGY COMPASS, 2016, 10 (01): : 74 - 86
  • [37] Partial Progress: Governing the Pharmaceutical Industry and the NHS, 1948-2008
    Abraham, John
    [J]. JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2009, 34 (06) : 931 - 977
  • [38] Digitalization in pharmaceutical industry: What to focus on under the digital implementation process?
    Hole, Glenn
    Hole, Anastasia S.
    McFalone-Shaw, Ian
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS-X, 2021, 3
  • [39] Pharmaceutical industry riding the wave of sustainability: Review and opportunities for future research
    Milanesi, Matilde
    Runfola, Andrea
    Guercini, Simone
    [J]. JOURNAL OF CLEANER PRODUCTION, 2020, 261
  • [40] NOISE IN THE INDUSTRY - THREAT FOR HEALTH
    Irimia, Alin
    Gaman, George Artur
    Simion, Sorin
    Calamar, Angela
    Pupazan, Daniel
    [J]. MANAGEMENT SYSTEMS IN PRODUCTION ENGINEERING, 2015, 19 (03) : 138 - 141